• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VHL 抑制 RAPTOR 并抑制肾透明细胞癌中的 mTORC1 信号通路。

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma.

机构信息

Renal Division, Department of Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

出版信息

Sci Rep. 2021 Jul 21;11(1):14827. doi: 10.1038/s41598-021-94132-5.

DOI:10.1038/s41598-021-94132-5
PMID:34290272
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8295262/
Abstract

Inactivation of the tumor suppressor von Hippel-Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC). The mechanistic target of rapamycin (mTOR) signaling pathway is a fundamental regulator of cell growth and proliferation, and hyperactivation of mTOR signaling is a common finding in VHL-dependent ccRCC. Deregulation of mTOR signaling correlates with tumor progression and poor outcome in patients with ccRCC. Here, we report that the regulatory-associated protein of mTOR (RAPTOR) is strikingly repressed by VHL. VHL interacts with RAPTOR and increases RAPTOR degradation by ubiquitination, thereby inhibiting mTORC1 signaling. Consistent with hyperactivation of mTORC1 signaling in VHL-deficient ccRCC, we observed that loss of vhl-1 function in C. elegans increased mTORC1 activity, supporting an evolutionary conserved mechanism. Our work reveals important new mechanistic insight into deregulation of mTORC1 signaling in ccRCC and links VHL directly to the control of RAPTOR/mTORC1. This may represent a novel mechanism whereby loss of VHL affects organ integrity and tumor behavior.

摘要

抑癌基因 von Hippel-Lindau(VHL)的失活是遗传性和散发性肾透明细胞癌(ccRCC)的关键事件。雷帕霉素(mTOR)信号通路的机械靶标是细胞生长和增殖的基本调节剂,mTOR 信号的过度激活是 VHL 依赖性 ccRCC 的常见发现。mTOR 信号的失调与 ccRCC 患者的肿瘤进展和不良预后相关。在这里,我们报告说,mTOR 的调节相关蛋白(RAPTOR)被 VHL 显著抑制。VHL 与 RAPTOR 相互作用,并通过泛素化增加 RAPTOR 的降解,从而抑制 mTORC1 信号。与 VHL 缺陷型 ccRCC 中 mTORC1 信号的过度激活一致,我们观察到秀丽隐杆线虫中 vhl-1 功能的丧失增加了 mTORC1 的活性,支持了一种进化保守的机制。我们的工作揭示了 ccRCC 中 mTORC1 信号失调的重要新机制,并将 VHL 直接与 RAPTOR/mTORC1 的控制联系起来。这可能代表了一种新的机制,即 VHL 的缺失影响器官完整性和肿瘤行为。

相似文献

1
VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma.VHL 抑制 RAPTOR 并抑制肾透明细胞癌中的 mTORC1 信号通路。
Sci Rep. 2021 Jul 21;11(1):14827. doi: 10.1038/s41598-021-94132-5.
2
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.von Hippel-Lindau 肿瘤抑制蛋白通过组蛋白去甲基酶 JARID1C 调节基因表达和肿瘤生长。
Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.
3
MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40.MELK 在高级透明细胞肾细胞癌中上调,并通过磷酸化 PRAS40 促进疾病进展。
Cell Transplant. 2019 Dec;28(1_suppl):37S-50S. doi: 10.1177/0963689719890860. Epub 2019 Dec 8.
4
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.SWI/SNF蛋白PBRM1抑制VHL缺失驱动的肾透明细胞癌。
Cell Rep. 2017 Mar 21;18(12):2893-2906. doi: 10.1016/j.celrep.2017.02.074.
5
MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.微小RNA-185通过直接靶向血管内皮生长因子A(VEGFA)抑制VHL基因失活的透明细胞肾细胞癌的细胞增殖并诱导细胞凋亡。
Urol Oncol. 2015 Apr;33(4):169.e1-11. doi: 10.1016/j.urolonc.2015.01.003. Epub 2015 Feb 17.
6
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.PTEN 抑制 YY1 诱导 von-Hippel-Lindau 缺失型肾细胞癌中的 HIF-2 活性。
Cancer Biol Ther. 2009 Jul;8(14):1389-401. doi: 10.4161/cbt.8.14.8880. Epub 2009 Jul 30.
7
MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.微小RNA-214降低肾癌细胞中胰岛素样生长因子-1(IGF-1)受体表达及下游mTORC1信号传导
J Biol Chem. 2016 Jul 8;291(28):14662-76. doi: 10.1074/jbc.M115.694331. Epub 2016 May 13.
8
Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.在透明细胞肾细胞癌中,冯·希佩尔-林道(VHL)的突变版本可保护缺氧诱导因子1α(HIF1α)免受SART1介导的降解。
Oncogene. 2016 Feb 4;35(5):587-94. doi: 10.1038/onc.2015.113. Epub 2015 Apr 27.
9
SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC.VHL 对 SCD5 的调控影响 ccRCC 中的细胞增殖和脂质稳态。
Cells. 2023 Mar 8;12(6):835. doi: 10.3390/cells12060835.
10
Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.定量蛋白质组学研究靶向肾细胞癌中希佩尔-林道蛋白缺失的小分子。
Int J Cancer. 2017 Aug 15;141(4):778-790. doi: 10.1002/ijc.30774. Epub 2017 May 25.

引用本文的文献

1
Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.接受肾移植评估患者的肾细胞癌临床特征及突变频率
Front Oncol. 2025 May 29;15:1526545. doi: 10.3389/fonc.2025.1526545. eCollection 2025.
2
Designed gramicidin-inspired stabilized peptide-based therapeutics to potentiate immunotherapy against aggressive kidney cancer.设计了受短杆菌肽启发的稳定化肽基疗法,以增强针对侵袭性肾癌的免疫疗法。
Biomater Sci. 2025 Jun 9. doi: 10.1039/d5bm00109a.
3
Extensive genotype-phenotype heterogeneity in renal cell carcinoma - a proof-of-concept study.

本文引用的文献

1
Targeting the HIF2-VEGF axis in renal cell carcinoma.靶向肾细胞癌中的 HIF2-VEGF 轴。
Nat Med. 2020 Oct;26(10):1519-1530. doi: 10.1038/s41591-020-1093-z. Epub 2020 Oct 5.
2
The acetyltransferase p300 regulates NRF2 stability and localization.乙酰转移酶 p300 调节 NRF2 的稳定性和定位。
Biochem Biophys Res Commun. 2020 Apr 16;524(4):895-902. doi: 10.1016/j.bbrc.2020.02.006. Epub 2020 Feb 10.
3
Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.全基因组筛选鉴定 SFMBT1 为 VHL 缺失型癌症中的致癌驱动基因。
肾细胞癌中广泛的基因型-表型异质性——一项概念验证研究。
Front Oncol. 2025 Apr 25;15:1551077. doi: 10.3389/fonc.2025.1551077. eCollection 2025.
4
VHL ameliorates arecoline-induced oral submucosal fibrosis by promoting HDAC6 ubiquitination and blocking NF-κB pathway.VHL通过促进HDAC6泛素化和阻断NF-κB信号通路改善槟榔碱诱导的口腔黏膜下纤维化。
Sci Rep. 2025 Mar 4;15(1):7563. doi: 10.1038/s41598-025-91207-5.
5
Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.透明细胞肾细胞癌的肿瘤起始细胞和转移起始细胞
J Biomed Sci. 2025 Feb 8;32(1):17. doi: 10.1186/s12929-024-01111-9.
6
Dysregulation of ubiquitination modification in renal cell carcinoma.肾细胞癌中泛素化修饰的失调
Front Genet. 2024 Dec 19;15:1453191. doi: 10.3389/fgene.2024.1453191. eCollection 2024.
7
Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: A comprehensive review.冯·希佩尔-林道综合征分子机制及临床意义的研究进展:综述
Transl Oncol. 2025 Jan;51:102193. doi: 10.1016/j.tranon.2024.102193. Epub 2024 Nov 21.
8
Genetics, Pathophysiology, and Current Challenges in Von Hippel-Lindau Disease Therapeutics.冯·希佩尔-林道病治疗中的遗传学、病理生理学及当前挑战
Diagnostics (Basel). 2024 Aug 29;14(17):1909. doi: 10.3390/diagnostics14171909.
9
Renal cancer: signaling pathways and advances in targeted therapies.肾癌:信号通路与靶向治疗进展
MedComm (2020). 2024 Aug 1;5(8):e676. doi: 10.1002/mco2.676. eCollection 2024 Aug.
10
Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.von Hippel-Lindau 蛋白信号在透明细胞肾细胞癌中的作用。
Nat Rev Urol. 2024 Nov;21(11):662-675. doi: 10.1038/s41585-024-00876-w. Epub 2024 May 2.
Mol Cell. 2020 Mar 19;77(6):1294-1306.e5. doi: 10.1016/j.molcel.2020.01.009. Epub 2020 Feb 4.
4
mTOR at the nexus of nutrition, growth, ageing and disease.mTOR 在营养、生长、衰老和疾病的交汇点。
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203. doi: 10.1038/s41580-019-0199-y. Epub 2020 Jan 14.
5
Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.基于超过 500 种人类癌症的基于质谱的蛋白质组学特征分析揭示的泛癌分子亚型。
Nat Commun. 2019 Dec 12;10(1):5679. doi: 10.1038/s41467-019-13528-0.
6
HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer.低氧诱导因子介导的DEPTOR抑制赋予肾癌对mTOR激酶抑制的抗性。
iScience. 2019 Nov 22;21:509-520. doi: 10.1016/j.isci.2019.10.047. Epub 2019 Oct 26.
7
Mitochondrial Perturbations Couple mTORC2 to Autophagy in C. elegans.线粒体扰动将 mTORC2 与线虫中的自噬作用偶联。
Cell Rep. 2019 Nov 5;29(6):1399-1409.e5. doi: 10.1016/j.celrep.2019.09.072.
8
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的综合蛋白质基因组特征分析。
Cell. 2019 Oct 31;179(4):964-983.e31. doi: 10.1016/j.cell.2019.10.007.
9
TOR Signaling in Development, Metabolism, and Aging.TOR 信号通路在发育、代谢和衰老中的作用。
Genetics. 2019 Oct;213(2):329-360. doi: 10.1534/genetics.119.302504.
10
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.全球、区域和国家癌症发病率、死亡率、生命损失年数、失能生存年数以及 29 种癌症组别的伤残调整生命年数:1990 至 2017 年全球疾病负担研究的系统分析。
JAMA Oncol. 2019 Dec 1;5(12):1749-1768. doi: 10.1001/jamaoncol.2019.2996.